Pfizer seeks to prevent HIV

A new Pfizer Inc. HIV drug will soon be reformulated in an effort to prevent the transmission of the virus. The New York drug maker is expected to announce that it will license its new medicine, Selzentry, to a nonprofit that investigates ways to turn HIV medicines for infected patients into vaginal substances to prevent transmission to women during sex. The partnership offers a low-risk way for Pfizer to find out if the medicine could become a frequently taken drug, while potentially offering an empowering concept to women in the developing world.